LIST OF TABLES

Table No. Page No.

Chapter 1: Introduction

1.01 Allowable changes in chromatography as per USP 20
1.02 Name, chemical structure, activity of selected drugs 21

Chapter 2: Literature survey

2.01 Lacosamide impurity details 27
2.02 Aliskerin impurity details 28
2.03 Febuxostat impurity details 29
2.04 Sildenafil citrate related compounds details 30
2.05 Bosentan impurity details 31

Chapter 4: Experimental investigations results and discussion on results.

4.1 Lacosamide
4.01 Finalized conditions 45
4.02 System suitability results 47
4.03 LOD and LOQ data 48
4.04 Precision and accuracy at LOQ 49
4.05 Impurity-1 linearity data 50
4.06 Impurity-2 linearity data 51
4.07 Impurity-3 linearity data 52
4.08 Impurity-4 linearity data 53
4.09 Impurity Accuracy data 54
4.10 Impurity precision data 55
4.11 Robustness- flow variation data 56
4.12 Robustness- temperature variation data 56
4.13 Robustness- pH variation data 57
4.14 Impurity solution stability data 57
4.15 Impurity mobile phase stability data  58
4.16 Assay System suitability results  58
4.17 Assay linearity data  59
4.18 Assay accuracy data  60
4.19 Assay precision data  61
4.20 Assay solution stability and mobile phase stability  62
4.21 Equivalency results  63

4.4 Aliskerin

4.22 Brief summary of experiments  66
4.23 Forced degradation results summary  70
4.24 Finalized method conditions  70
4.25 Gradient programme  71
4.26 System suitability results  73
4.27 LOD and LOQ Data  73
4.28 Precision and accuracy at LOQ  74
4.29 Impurity-1 linearity data  75
4.30 Impurity-2 linearity data  76
4.31 Impurity-3 linearity data  77
4.32 Impurity-4 linearity data.  78
4.33 Impurity accuracy data  80
4.34 Impurity precision data  80
4.35 Robustness- flow variation data  81
4.36 Robustness- temperature variation data  81
4.37 Robustness- pH variation data  82
4.38 Impurity solution stability and mobile phase data  82
4.39 Assay System suitability results  83
4.40 Assay linearity data  84
4.41 Assay accuracy data  85
4.42 Assay precision data  86
4.43  Assay solution stability and mobile phase stability 87
4.44  Equivalency test results 88

4.5  Febuxostat
4.45  Summary on development experiments 91
4.46  Stress study summary 95
4.47  Finalized method conditions 96
4.48  Gradient programme 96
4.49  System suitability results 98
4.50  LOD and LOQ Data 98
4.51  Impurity-1 linearity data 100
4.52  Impurity-2 linearity data 101
4.53  Impurity-3 linearity data 102
4.54  Impurity-4 linearity data 103
4.55  Impurity-5 linearity data 104
4.56  Impurity-6 linearity data 105
4.57  Impurity accuracy data 107
4.58  Impurity precision data 107
4.59  Robustness-flow variation data 108
4.60  Robustness-temperature variation data 108
4.61  Robustness-pH variation data 109
4.62  Impurity solution stability data 109
4.63  Assay System suitability results 110
4.64  Assay linearity and accuracy data 111
4.65  Assay precision data 112
4.66  Assay solution stability and mobile phase stability 114
4.67  Equivalency results 114

4.6  Sildenafil citrate
4.68  Method development trails summary 118
4.69  Forced degradation results summary 122
4.70 Finalized method conditions 122
4.71 Gradient programme 123
4.72 System suitability results 124
4.73 LOD and LOQ Data 125
4.74 RC-01 linearity data 127
4.75 RC-02 linearity data 128
4.76 RC-03 linearity data 129
4.77 RC-04 linearity data 130
4.78 Impurity accuracy data 131
4.79 Impurity precision data 132
4.80 Robustness- flow variation data 132
4.81 Robustness- temperature variation data 133
4.82 Impurity solution stability data 133
4.83 Assay System suitability results 134
4.84 Assay linearity and accuracy data 135
4.85 Assay precision data 136
4.86 Assay solution stability and mobile phase stability 137
4.87 Equivalency test results 138

**4.7 Bosentan**

4.88 Method development trails summary 142
4.89 Forced degradation results summary 146
4.90 Finalized method conditions 146
4.91 Gradient programme 147
4.92 System suitability results 148
4.93 LOD and LOQ Data 148
4.94 Precision and accuracy at LOQ 150
4.95 Impurity-1 linearity data 151
4.96 Impurity-2 linearity data 152
4.97 Impurity-3 linearity data 153
4.98  Impurity-4 linearity data  
4.99  Impurity-5 linearity data  
4.100 Impurity-6 linearity data  
4.101 Impurity accuracy data  
4.102 Impurity precision data  
4.103 Robustness- flow variation data  
4.104 Robustness- temperature variation data  
4.105 Impurity solution stability data  
4.106 Assay System suitability results  
4.107 Assay linearity and accuracy data  
4.108 Assay precision data  
4.109 Assay solution stability and mobile phase stability  
4.110 Equivalency test results
LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure No.</th>
<th>Description</th>
<th>Page No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chapter 2: Literature survey</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.01</td>
<td>Structure of Lacosamide</td>
<td>26</td>
</tr>
<tr>
<td>2.02</td>
<td>Structure of Aliskerin</td>
<td>27</td>
</tr>
<tr>
<td>2.03</td>
<td>Structure of Febuxostat</td>
<td>28</td>
</tr>
<tr>
<td>2.04</td>
<td>Structure of Sildenafil citrate</td>
<td>30</td>
</tr>
<tr>
<td>2.05</td>
<td>Structure of Bosentan</td>
<td>31</td>
</tr>
<tr>
<td>Chapter 4: Experiments, investigations and conclusions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.01</td>
<td>Amino impurity UV Spectrum</td>
<td>40</td>
</tr>
<tr>
<td>4.02</td>
<td>Hydroxy impurity UV Spectrum</td>
<td>41</td>
</tr>
<tr>
<td>4.03</td>
<td>Acetamide impurity UV Spectrum</td>
<td>41</td>
</tr>
<tr>
<td>4.04</td>
<td>Lacosamide UV Spectrum</td>
<td>41</td>
</tr>
<tr>
<td>4.05</td>
<td>O-Acetyl impurity UV Spectrum</td>
<td>41</td>
</tr>
<tr>
<td>4.06</td>
<td>Thermal degraded sample chromatogram</td>
<td>43</td>
</tr>
<tr>
<td>4.07</td>
<td>Light degraded sample chromatogram.</td>
<td>43</td>
</tr>
<tr>
<td>4.08</td>
<td>Acid degraded sample chromatogram</td>
<td>44</td>
</tr>
<tr>
<td>4.09</td>
<td>Base degraded sample chromatogram</td>
<td>44</td>
</tr>
<tr>
<td>4.10</td>
<td>Peroxide degraded sample chromatogram</td>
<td>45</td>
</tr>
<tr>
<td>4.11</td>
<td>Diluent chromatogram</td>
<td>46</td>
</tr>
<tr>
<td>4.12</td>
<td>Placebo chromatogram</td>
<td>46</td>
</tr>
<tr>
<td>4.13</td>
<td>System suitability chromatogram</td>
<td>46</td>
</tr>
<tr>
<td>4.14</td>
<td>Impurity-1 linearity graph</td>
<td>51</td>
</tr>
<tr>
<td>4.15</td>
<td>Impurity-2 linearity graph</td>
<td>52</td>
</tr>
<tr>
<td>4.16</td>
<td>Impurity-3 linearity graph</td>
<td>52</td>
</tr>
<tr>
<td>4.17</td>
<td>Impurity-4 linearity graph</td>
<td>53</td>
</tr>
<tr>
<td>4.18</td>
<td>Assay linearity graph</td>
<td>60</td>
</tr>
</tbody>
</table>
4.2 Aliskerin

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.19</td>
<td>Aliskerin UV Spectrum</td>
<td>64</td>
</tr>
<tr>
<td>4.20</td>
<td>Impurity-1 UV Spectrum</td>
<td>64</td>
</tr>
<tr>
<td>4.21</td>
<td>Impurity-2 UV Spectrum</td>
<td>65</td>
</tr>
<tr>
<td>4.22</td>
<td>Impurity-3 UV Spectrum</td>
<td>65</td>
</tr>
<tr>
<td>4.23</td>
<td>Impurity-4 UV Spectrum</td>
<td>65</td>
</tr>
<tr>
<td>4.24</td>
<td>Thermal degraded sample chromatogram</td>
<td>67</td>
</tr>
<tr>
<td>4.25</td>
<td>Light degraded sample chromatogram</td>
<td>67</td>
</tr>
<tr>
<td>4.26</td>
<td>Acid degraded sample chromatogram</td>
<td>68</td>
</tr>
<tr>
<td>4.27</td>
<td>Base degraded sample chromatogram</td>
<td>68</td>
</tr>
<tr>
<td>4.28</td>
<td>Peroxide degraded sample chromatogram</td>
<td>69</td>
</tr>
<tr>
<td>4.29</td>
<td>Water degraded sample chromatogram</td>
<td>69</td>
</tr>
<tr>
<td>4.30</td>
<td>Diluent chromatogram</td>
<td>71</td>
</tr>
<tr>
<td>4.31</td>
<td>Placebo chromatogram</td>
<td>71</td>
</tr>
<tr>
<td>4.32</td>
<td>System suitability chromatogram</td>
<td>72</td>
</tr>
<tr>
<td>4.33</td>
<td>Impurity-1 linearity graph</td>
<td>76</td>
</tr>
<tr>
<td>4.34</td>
<td>Impurity-2 linearity graph</td>
<td>77</td>
</tr>
<tr>
<td>4.35</td>
<td>Impurity-3 linearity graph</td>
<td>78</td>
</tr>
<tr>
<td>4.36</td>
<td>Impurity-4 linearity graph</td>
<td>79</td>
</tr>
<tr>
<td>4.37</td>
<td>Assay linearity graph</td>
<td>85</td>
</tr>
</tbody>
</table>

4.3 Febuxostat

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.38</td>
<td>Febuxostat UV Spectrum</td>
<td>89</td>
</tr>
<tr>
<td>4.39</td>
<td>Impurity-1 UV Spectrum</td>
<td>89</td>
</tr>
<tr>
<td>4.40</td>
<td>Impurity-2 UV Spectrum</td>
<td>89</td>
</tr>
<tr>
<td>4.41</td>
<td>Impurity-3 UV Spectrum</td>
<td>90</td>
</tr>
<tr>
<td>4.42</td>
<td>Impurity-4 UV Spectrum</td>
<td>90</td>
</tr>
<tr>
<td>4.43</td>
<td>Impurity-5 UV Spectrum</td>
<td>90</td>
</tr>
<tr>
<td>4.44</td>
<td>Impurity-6 UV Spectrum</td>
<td>90</td>
</tr>
<tr>
<td>4.45</td>
<td>Thermal degraded sample chromatogram</td>
<td>92</td>
</tr>
<tr>
<td>4.46</td>
<td>Light degraded sample chromatogram</td>
<td>93</td>
</tr>
<tr>
<td>4.47</td>
<td>Acid degraded sample chromatogram</td>
<td>93</td>
</tr>
</tbody>
</table>
4.48  Base degraded sample chromatogram 94
4.49  Peroxide degraded sample chromatogram 94
4.50  Water degraded sample chromatogram 95
4.51  Diluent chromatogram 96
4.52  Placebo chromatogram 97
4.53  System suitability chromatogram 97
4.54  Impurity-1 linearity graph 101
4.55  Impurity-2 linearity graph 102
4.56  Impurity-3 linearity graph 103
4.57  Impurity-4 linearity graph 104
4.58  Impurity-5 linearity graph 105
4.59  Impurity-6 linearity graph 106
4.60  Assay linearity graph 112

4.4 Sildenafil citrate
4.61  Sildenafil citrate UV Spectrum 116
4.62  Related compound-01 UV Spectrum 116
4.63  Related compound-02 UV Spectrum 116
4.64  Related compound-03 UV Spectrum 117
4.65  Related compound-04 UV Spectrum 117
4.66  Thermal degraded sample chromatogram 119
4.67  Light degraded sample chromatogram 119
4.68  Acid degraded sample chromatogram 120
4.69  Base degraded sample chromatogram 120
4.70  Peroxide degraded sample chromatogram 121
4.71  Water degraded sample chromatogram 121
4.72  Diluent chromatogram 123
4.73  Placebo chromatogram 123
4.74  System suitability chromatogram 123
4.75  Related compound-01 linearity graph 127
4.76  Related compound-02 linearity graph 128
4.77  Related compound-03 linearity graph 129
4.78 Related compound-04 linearity graph 130
4.79 Assay linearity 135

4.5 Bosentan

4.80 Bosentan UV Spectrum 139
4.81 Impurity-01 UV Spectrum 139
4.82 Impurity-02 UV Spectrum 139
4.83 Impurity-03 UV Spectrum 140
4.84 Impurity-04 UV Spectrum 140
4.85 Impurity-05 UV Spectrum 140
4.86 Impurity-06 UV Spectrum 141
4.87 Thermal degraded sample chromatogram 143
4.88 Light degraded sample chromatogram 143
4.89 Acid degraded sample chromatogram 144
4.90 Base degraded sample chromatogram 144
4.91 Peroxide degraded sample chromatogram 145
4.92 Water degraded sample chromatogram 145
4.93 Diluent chromatogram 147
4.94 Placebo chromatogram 147
4.95 System suitability chromatogram 147
4.96 Impurity-1linearity graph 151
4.97 Impurity-2linearity graph 152
4.98 Impurity-3linearity graph 153
4.99 Impurity-4linearity graph 154
4.100 Impurity-5linearity graph 155
4.101 Impurity-6linearity graph 156
4.102 Assay linearity 161